Idiopathic Respiratory Distress Syndrome

Phase III Clinical Trial Launched In Europe And U.S.

Published in TB and Outbreaks Week, October 16th, 2001

Discovery Laboratories, Inc. announces the initiation of patient enrollment in a supportive Phase III multinational clinical trial evaluating Surfaxin (lucinactant) for the prevention and treatment of idiopathic respiratory distress syndrome (IRDS) in premature infants.

This second Phase III IRDS trial is designed to demonstrate the safety and non-inferiority of Surfaxin, Discovery's humanized, synthesized, peptide-containing surfactant, over a leading animal-derived surfactant in Europe thus providing support to Discovery's previously announced pivotal Phase III multinational IRDS clinical trial. Approximately 500 patients in Europe as well as the United States will...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2001-10-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry